Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)
Sino-US biotech Laekna Therapeutics (HKG: 2105) and Qilu Pharmaceutical Co., Ltd. announced today an exclusive...
HKG: 2105
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials
Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval...
Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New...
Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...
Sino-US Laekna’s LAE102 Clinical Trial Filing Accepted for Review in Obesity and Metabolic Disorders
Sino-US Laekna (HKG: 2105) has announced that its clinical trial application for LAE102, an antibody...
Laekna Raises £791 Million in Hong Kong IPO for Pipeline Expansion
Sino-US Laekna (HKG: 2105) has successfully raised £791 million through an initial public offering (IPO)...